Evidence map›Paper›PMID 30875057›Full record

ReviewEndocrine2019

Novel PET tracers: added value for endocrine disorders.

Sébastien Bergeret, Judith Charbit, Catherine Ansquer, Géraldine Bera, Philippe Chanson, Charlotte Lussey-Lepoutre

Abstract readReview
PubMed Publisher
In one paragraph

Review in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.

  1. Pooled it
  2. The role ofEJNMMI research · 2019
    Article
  3. Non-FDG PET/CT in Diagnostic Oncology: a pictorial review.European journal of hybrid imaging · 2019
    Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Sébastien BergeretSorbonne University, Nuclear Medicine Department, Pitié-Salpêtrière Hospital, 47-83 Bd de l'Hôpital, 75013, Paris, France.
Judith CharbitSorbonne University, Nuclear Medicine Department, Pitié-Salpêtrière Hospital, 47-83 Bd de l'Hôpital, 75013, Paris, France.
Catherine AnsquerNuclear Medicine Department, CHU-Hôtel Dieu, 1 Place Alexis Ricordeau, 44093, Nantes Cedex1, France.
Géraldine BeraSorbonne University, Nuclear Medicine Department, Pitié-Salpêtrière Hospital, 47-83 Bd de l'Hôpital, 75013, Paris, France.
Philippe ChansonAssistance Publique-Hôpitaux de Paris, Hôpital de Bicêtre, Service d'Endocrinologie et des Maladies de la Reproduction, Centre de Référence des Maladies Rares de l'Hypophyse, Le Kremlin Bicêtre, F-94275, France.
Charlotte Lussey-LepoutreSorbonne University, Nuclear Medicine Department, Pitié-Salpêtrière Hospital, 47-83 Bd de l'Hôpital, 75013, Paris, France. charlotte.lussey@inserm.fr.
Inserm · FRSorbonne Université · FRUniversité Paris-Sud · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nuclear medicine has been implicated in the diagnosis and treatment of endocrine disorders for several decades. With recent development of PET tracers, functional imaging now plays a major role in endocrine tumors enabling with high performance to their localization, characterization, and staging. Besides

Indexed as

RadiopharmaceuticalsDihydroxyphenylalanineEndocrine System DiseasesFluorodeoxyglucose F18Gallium RadioisotopesHumansNeuroendocrine TumorsPositron-Emission TomographyDihydroxyphenylalanineFluorodeoxyglucose F18fluorodopa F 18Gallium-68Gallium RadioisotopesRadiopharmaceuticals18F-Choline18F-FDG18F-FDOPAGallium-68Neuroendocrine tumorsPET/CTPrimary hyperparathyroidismSomatostatin

Identifiers

PMID30875057
OpenAlexW2920891858

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.